Biodelivery sciences prevails in belbuca® anda litigation maintaining patent exclusivity against alvogen until 2032

Raleigh, n.c., dec. 20, 2021 (globe newswire) -- biodelivery sciences international, inc. (nasdaq: bdsi), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the u.s. district court of delaware has issued an opinion in favor of bdsi in the company's patent litigation against alvogen group, inc. and its affiliates, who filed an abbreviated new drug application (anda) for bdsi's belbuca® product on may 23, 2018. the opinion by the trial judge upholds the validity of claims in bdsi's patents 8,147,866 (the ‘866 patent), which expires in 2027, and 9,901,539 (the ‘539 patent), which expires in 2032. alvogen conceded infringement of these claims. accordingly, bdsi expects market exclusivity of belbuca against alvogen until 2032.
BDSI Ratings Summary
BDSI Quant Ranking